Exhibit 10.2
VIRACTA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
This Employment Agreement (this “Agreement”) by and between Viracta Therapeutics, Inc. (the “Company”) and Darrel P. Cohen, M.D., Ph.D. (“Executive”) is effective as of August 7, 2023 (the “Effective Date”).
2
will be subject to the terms and conditions of the Plans and any form of stock option agreement issued thereunder.
3
payments will be made regardless of whether the Executive elects COBRA continuation coverage and will commence in the month following the month of the termination date and continue for the period of months indicated in this section;
4
Termination, any severance payments and benefits to be provided to the Executive under Section 5(b) will be reduced by any amounts that already were provided to the Executive under Section 5(a).
5
In no event will Executive have any discretion with respect to the ordering of payments or benefits.
6
Separation Benefits”) will be paid or otherwise provided until Executive has a “separation from service” within the meaning of Section 409A.
(60) day period immediately following Executive’s separation from service but for the preceding sentence will be paid to Executive on the sixtieth (60th) day following Executive’s separation from service and the remaining payments shall be made as provided in this Agreement.
(i) above.
7
(ii) Executive’s conviction of, or plea of nolo contendere to, a felony or any crime involving fraud, embezzlement or any other act of moral turpitude, (iii) Executive’s gross misconduct,
(iv) Executive’s unauthorized use or disclosure of any proprietary information or trade secrets of the Company or any other party to whom Executive owes an obligation of nondisclosure as a result of Executive’s relationship with the Company; (v) Executive’s willful breach of any obligations under any written agreement or covenant with the Company; or (vi) Executive’s continued failure to perform Executive’s employment duties after Executive has received a written demand of performance from the Company which specifically sets forth the factual basis for the Company’s belief that Executive has not substantially performed Executive’s duties and has failed to cure such non-performance to the Company’s satisfaction within 10 business days after receiving such notice.
8
9
days after being mailed by registered or certified mail, return receipt requested, prepaid and addressed to the parties or their successors at the following addresses, or at such other addresses as the parties may later designate in writing:
If to the Company:
Viracta Therapeutics, Inc.
2533 South Coast Highway 101, Suite 210
Cardiff, CA 92007
Attn: Chief Executive Officer
If to Executive:
at the last residential address known by the Company.
10
Remainder of Page Intentionally Left Blank
11
IN WITNESS WHEREOF, each of the parties has executed this Agreement (in the case of the Company, by a duly authorized officer or director), effective as of the Effective Date.
COMPANY:
VIRACTA THERAPEUTICS, INC.
/s/ Mark Rothera
By: Mark Rothera
Title: President & CEO
EXECUTIVE:
DARREL P. COHEN, M.D., Ph.D.
/s/ Darrel Cohen
12